Conference Reports for NATAP

Back

IDWeek October 3 -7 2018 San Francisco, CA     U=U Pro.... - (10/15/18)   With HIV, Does U=U (Undetectable = Untransmittable)? Uh, well, maybe not...... - (10/13/18)   PHARMACOKINETIC PROFILE OF IBALIZUMAB FROM A PHASE 3 TRIAL - (10/13/18)   Investigating the Mechanism of a Unique Human Immunodeficiency Virus-1 (HIV-1) Entry Inhibitor, MF275 - (10/13/18)   No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-administration - (10/13/18)   MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol - (10/13/18)   Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States - good picture of the aging generation - (10/13/18)   Retrospective Analysis of Clinical Characteristics and Treatment Patterns among HIV Patients with Commercial and Medicare Advantage Health Insurance in the US: high comorbidities & polypharmacy rates increasing with age - (10/13/18)   Adherence and Persistency with Modern Single vs Multi-Tablet Antiretroviral (ARV) Regimens in 1st treatment of HIV in Clinical Practice - (10/13/18)   Evaluation of Relationships Between UGT1A1Genotypes and Cabotegravir Long-Acting Injection Pharmacokinetics Among HIV-Infected Subjects in the LATTE-2 Study - (10/13/18)   An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults - (10/13/18)   With HIV, Does U=U (Undetectable = Untransmittable)? Uh, well, maybe not...... - (10/13/18)   Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1-6 and Human Immunodeficiency Virus-1 Coinfection: An Integrated Analysis of Two Phase 3 Clinical Trials - (10/12/18)   The aging epidemic: virologic control, immunologic recovery, treatment regimens, and clinical outcomes among older adults living with HIV in Washington, DC: Long-Term CD4 and Viral Rebound Trends Worse Over Age 59 Than at 18 to 35 - Mark Mascolini (10/12/18)   Hospitalization rates among persons with HIV who gained Medicaid or private insurance in 2014: Moving From Ryan White to Medicaid or Private Insurance Did Not Boost Hospital Use; BUT Older HIV+ 55-64 Had Double the Hospitalization Rate; Low CD4 & Detectable Viral load also had Higher Hospitalization Rates (10/12/18)   Immune recovery of acute HIV treated patients is characterized by an increase in immune senescence. (10/12/18)   Rational Design of Doravirine (DOR): A Review of Development From Bench to Patients (10/12/18)   The Hepatitis C Virus Cascade of Care at Stony Brook University Hospital: Risk Factors for Linkage to Care (20% linkage to care) (10/12/18)   Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results From the German Hepatitis C-Registry (10/12/18)   Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir (10/12/18)   Hospital Rates Rise With Age for Cancer, Cardio, Other Diseases in US HIV Group - Mark Mascolini (10/10/18)   HCV Testing Among Adolescents and Young Adults in a National Sample of Federally Qualified Health Centers - (10/10/18)   Only 30% With HCV/HIV in Safety-Net System Get HCV Therapy in DAA Era - Hepatitis C eradication: who is being left behind in the HIV population? - Mark Mascolini - (10/10/18)   Key factors for treatment changes within one year after starting ART in the German ClinSurv Cohort; between 2005 and 2017: Higher Pretreatment Load, More Pills Predict Faster ART Stop or Switch - Mark Mascolini (10/10/18)   Improving HIV outcomes among HIV-infected patients diagnosed with cancer and followed in an integrated, multidisciplinary, infectious disease/cancer clinic: Better CD4 and Viral Load Outcomes After Meshing HIV and Cancer Care - Mark Mascolini - (10/10/18)   Serum Albumin is Associated with Higher Inflammation and Carotid Atherosclerosis in Treated HIV Infection - (10/10/18)   Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis - (10/10/18)   A RETROSPECTIVE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A NUCLEOSIDE-SPARING REGIMEN OF DARUNAVIR, RITONAVIR AND DOLUTEGRAVIR - (10/10/18)   Week 96 results of the phase 3, randomized, non-inferiority EMERALD trial: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed adults living with HIV-1 - (10/10/18)   Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir - (10/09/18)   Only 30% With HCV/HIV in Safety-Net System Get HCV Therapy in DAA Era - Hepatitis C eradication: who is being left behind in the HIV population? - Mark Mascolini (10/09/18)   Week 96 results of the phase 3, randomized, non-inferiority EMERALD trial: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed adults living with HIV-1 - (10/09/18)   Sustained viral suppression with dolutegravir and boosted darunavir dual therapy among highly treatment-experienced individuals. Sustained Viral Suppression After Switch to Darunavir/Dolutegravir - Mark Mascolini(10/09/18)   Antiretrovirals Perturb Cholesterol Biosynthesis in PBMCs of HIV-Infected Individuals - (10/09/18)   Lung Cancer Chemotherapy Less Frequent With HIV, But Toxicity No Greater - Mark Mascolini (10/09/18)   Primary CNS Lymphoma Treatment Less Aggressive With HIV, But Survival Similar - Mark Mascolini (10/09/18)   Mail-Order Pharmacy, Travel Time to Pharmacy Do Not Affect HIV Control - Mark Mascolini (10/09/18)   Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions following initiation of commonly prescribed antiretrovirals - (10/09/18)   Delayed ART, Smoking, Sleep Apnea, PI, (CVD) Tied to Erectile Dysfunction With HIV - Mark Mascolini (10/09/18)   Mental Health Medications (Non-ARV meds) in Older HIV+ Appear to Cause Cognitive Impairment & Slow Gait Speed - Ethnicity, Insurance Differ in Older HIV Group Taking Mental Health Meds - Mark Mascolini - (10/09/18)   Virally Suppressed PLH Switching From Abacavir To Tenofovir Alafenamide Did Not Have Changes in Immune Activation or Inflammation - (10/06/18)   Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients - (10/06/18)   Doravirine/Lamivudine/Tenofovir DF continues to be Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-naïve Adults with HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial - (10/06/18)   Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial - (10/06/18)   A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 96 - (10/05/18)   Safety of in utero antiretroviral (ARV) exposure: neurologic outcomes in HIV-exposed, uninfected children - (10/05/18)   Results of Patient-Reported Outcome Data from the Phase III BRIGHTE Study of Fostemsavir - (10/05/18)   Half of 50-Plus HIV Group Lonely, But Loneliness Declines in the 60s - Mark Mascolini - (10/05/18)   In 60-Year-Plus HIV Group With Viral Suppression, 70% Have Low CD4:CD8 Ratio - Mark Mascolini - (10/05/18)   Predictors of cardiovascular outcomes in older HIV-infected patients: CORE50 Cohort 10-year follow-up / Framingham Score, Depression, Aspirin Predict Cardiovascular Events in Older People With HIV - Mark Mascolini - (10/05/18)   Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1 - (10/03/18)   Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy - (10/03/18)   Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging - (10/03/18)   Virologic Failure Rate No Higher in Blacks Than Whites in US Military - Mark Mascolini - (10/03/18)   GS-6207: A Novel, Potent and Selective First-In-Class Inhibitor of HIV 1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long Acting Potential in Humans - (10/03/18)   Integrase Inhibitors-based HAART is Associated with Greater BMI Gains in Blacks and Hispanics. - (10/03/18)   HIV More Advanced at Diagnosis in Older People, ART Response Slower - Mark Mascolini - (10/03/18)